The Latest in CML

Mortality in CML-CP patients receiving frontline second-generation TKIs

February 10, 2021

CML

CML: Biomarkers can predict relapse in patients on treatment-free remission

February 10, 2021

CML

Risk factors for COVID-19 mortality in patients with CML

February 10, 2021

CML

Factors influencing early molecular response to imatinib therapy in CML

January 13, 2021

CML

Adverse events in CML patients treated with TKIs

January 13, 2021

CML

Ph+ CML-CP: Bosutinib is effective across age groups and mCCI scores

January 13, 2021

CML

Personalized treatment recommendations in patients with CML-CP

January 13, 2021

CML

CML: Renal function decline in TKI users

January 13, 2021

CML

Conception-related outcomes of TKI-treated male patients with CML

January 13, 2021

CML

CML: TKI discontinuation is safe, improves patient-reported outcomes

January 13, 2021

CML

CML: Asciminib shows efficacy and safety in phase 3 ASCEMBL trial

January 13, 2021

CML

Hematology News

On the horizon: Asciminib, a new drug for treating r/r CML

December 16, 2020

Oncology Practice

Survey quantifies COVID-19’s impact on oncology

September 20, 2020

Hematology News

New data and trial outcomes clarify path to TFR in CML

September 18, 2020

CML

Hematology News

CML: New TKIs and combos show promise for resistant, intolerant disease

September 17, 2020

CML